Osiris Therapeutics (OSIR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2014 | 12-2013 | 09-2013 | 06-2013 | 03-2013 | |
| Sales | 10,054 | 8,080 | 6,882 | 5,291 | 4,055 |
| Cost of Goods | 2,212 | 2,181 | 1,858 | 1,482 | 1,135 |
| Gross Profit | 7,842 | 5,899 | 5,024 | 3,809 | 2,920 |
| Operating Expenses | 8,669 | 6,865 | 5,767 | 5,771 | 3,738 |
| Operating Income | -615 | -785 | 115 | -1,480 | -683 |
| Other Income | -126 | 334 | 26 | 25 | 29 |
| Pre-tax Income | -741 | -451 | 141 | -1,455 | -654 |
| Income Tax | -130 | -1,326 | 0 | 358 | -358 |
| Net Income Continuous | -611 | 875 | 141 | -1,813 | -296 |
| Net Income Discontinuous | -754 | 48,932 | -1,818 | -1,944 | -2,439 |
| Net Income | $-1,365 | $49,807 | $-1,677 | $-3,757 | $-2,735 |
| EPS Basic Total Ops | -0.04 | 1.50 | -0.05 | -0.12 | -0.08 |
| EPS Basic Continuous Ops | -0.02 | 0.03 | 0.00 | -0.06 | -0.01 |
| EPS Basic Discontinuous Ops | -0.02 | 1.47 | -0.05 | -0.06 | -0.07 |
| EPS Diluted Total Ops | -0.04 | 1.50 | -0.05 | -0.12 | -0.08 |
| EPS Diluted Continuous Ops | -0.02 | 0.03 | 0.00 | -0.06 | -0.01 |
| EPS Diluted Discontinuous Ops | -0.02 | 1.47 | -0.05 | -0.06 | -0.07 |
| EBITDA(a) | $-401 | $-471 | $117 | $-1,355 | $-537 |